Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

22.2%

2 terminated/withdrawn out of 9 trials

Success Rate

71.4%

-15.1% vs industry average

Late-Stage Pipeline

22%

2 trials in Phase 3/4

Results Transparency

140%

7 of 5 completed trials have results

Key Signals

1 recruiting7 with results

Enrollment Performance

Analytics

Phase 2

5(62.5%)

Phase 3

2(25.0%)

Phase 1

1(12.5%)

8Total

Phase 2(5)

Phase 3(2)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT07322003Phase 3Recruiting

Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS

Role: lead

NCT06069934Unknown

A Second Intermediate-Size Expanded Access Protocol (EAP) for Pridopidine in People With Amyotrophic Lateral Sclerosis (Pridopidine EAP 2)

Role: lead

NCT04556656Phase 3Completed

PRidopidine's Outcome On Function in Huntington Disease, PROOF- HD

Role: lead

NCT04615923Phase 2Completed

HEALEY ALS Platform Trial - Regimen D Pridopidine

Role: collaborator

NCT03922711Phase 2Terminated

A Study to Assess the Safety and Effectiveness of Pridopidine Compared to Placebo in the Treatment of Levodopa-Induced Dyskinesia in Patients With Parkinson's Disease

Role: lead

NCT01306929Phase 2Completed

Open-label Extension Study of Pridopidine (ACR16) in the Symptomatic Treatment of Huntington Disease

Role: lead

NCT03019289Phase 1Completed

A Study to Evaluate Sigma-1 and Dopamine-2 Receptor Occupancy by Pridopidine in the Human Brain of Healthy Volunteers and in Patients With Huntington's Disease

Role: lead

NCT02494778Phase 2Terminated

A Study Evaluating if Pridopidine is Safe, Efficacious, and Tolerable in Patients With Huntington's Disease

Role: lead

NCT02006472Phase 2Completed

A Phase 2, to Evaluating the Safety and Efficacy of Pridopidine Vs Placebo for Symptomatic Treatment in Patients With Huntington's Disease

Role: lead

All 9 trials loaded